FDA due to decide Saturday on Myqorzo label update

The company is not seeking first-line use, and payers still require beta-blockers first, even after MAPLE-HCM showed aficamten beat metoprolol.

By Theo Adeyemi, Regulation and biotech correspondent
. 2-minute read.
Headquarters building of Cytokinetics in South San Francisco, California
The Cytokinetics headquarters in South San Francisco, California, photographed in July 2023. Photograph: Coolcaesar/Wikimedia Commons (CC BY-SA 4.0)

The FDA is due to decide Saturday whether Cytokinetics may add data from its MAPLE-HCM trial to the label of Myqorzo (aficamten), a heart medication currently marketed in the U.S., Tech Times reported. No decision had been announced by either the company or the agency as of the report's writing. The supplemental application was accepted for filing and received a target decision date of November 14, 2026.

Myqorzo is approved for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms, based on the SEQUOIA-HCM trial, the company said in its December 2025 approval release cited in the article. Its label includes a boxed warning about heart failure, and the drug is available only under a Risk Evaluation and Mitigation Strategy program.

The MAPLE-HCM trial used a double-blind, double-dummy design and randomly assigned 175 adults with symptomatic oHCM to daily monotherapy with either aficamten at 5–20 mg or metoprolol at 50–200 mg. The findings were presented at ESC Congress 2025 and appeared in the New England Journal of Medicine. At 24 weeks, peak oxygen uptake increased by 1.1 mL/kg/min with aficamten and fell by 1.2 mL/kg/min with metoprolol, for a 2.3 mL/kg/min difference favoring aficamten. Resting outflow gradient was 30 mmHg lower with aficamten than with metoprolol, and Valsalva gradient was 35 mmHg lower; KCCQ-CSS symptom scores were 6.9 points higher on aficamten. Pablo Garcia-Pavia, the trial's principal investigator, said the findings "call into question the reliance on beta-blockers as the initial treatment modality".

Patients in this trial had less severe disease than those in SEQUOIA-HCM, the article notes. Hypertension occurred in 10.2% of aficamten patients versus 2.3% of metoprolol patients, and dizziness occurred in 17.2% of metoprolol patients versus 5.7% of aficamten patients. Aficamten lowered left ventricular ejection fraction by a mean 4% compared with metoprolol; a 69-year-old woman on aficamten who had multiple comorbidities died following a viral illness.

On a November 4 earnings call, Cytokinetics executives said the company is not seeking first-line status. Chief Commercial Officer Andrew Callos said, "We're not expecting nor are we pushing first line." Payer criteria still require prior beta-blocker use, and Callos said he is not looking to change that. The 2024 AHA/ACC guideline recommends starting symptomatic oHCM patients on non-vasodilating beta-blockers, and the ESC's 2025 release placed myosin inhibitors in the second-line setting. A few HCM specialists, including Martin Maron and Ahmad Masri, have said the evidence supports considering aficamten a "legitimate first-line option" for obstruction-related symptoms, but the trial's limits include being funded by Cytokinetics, a 24-week design that cannot show long-term outcomes, and the possibility that other beta-blockers may behave differently.

The drug brought in $44.5 million in net product revenue for the third quarter, with $43.1 million from the U.S. and $1.4 million from Europe. The company intends to seek approval for non-obstructive HCM in the fourth quarter and to file in Europe early in 2027, the article says.

Sources: Tech Times

Theo AdeyemiRegulation and biotech correspondent

Theo Adeyemi covers drug regulation and the biotech industry for Clinical Observer. He writes from regulators' notices, company filings and published reporting.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.